305 related articles for article (PubMed ID: 18094414)
1. HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Clin Cancer Res; 2007 Dec; 13(24):7329-34. PubMed ID: 18094414
[TBL] [Abstract][Full Text] [Related]
2. Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells.
Lu XL; Jiang XB; Liu RE; Zhang FC; Zhao HY
Cancer Lett; 2007 Oct; 256(1):128-35. PubMed ID: 17719173
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
4. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
Lu X; Jiang X; Liu R; Zhao H; Liang Z
Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
[TBL] [Abstract][Full Text] [Related]
7. Induction of cytotoxic T lymphocytes specific to malignant glioma using T2 cells pulsed with HLA-A2-restricted interleukin-13 receptor alpha 2 peptide in vitro.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Acta Biochim Biophys Sin (Shanghai); 2007 Sep; 39(9):641-8. PubMed ID: 17805458
[TBL] [Abstract][Full Text] [Related]
8. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
9. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
[TBL] [Abstract][Full Text] [Related]
10. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
[TBL] [Abstract][Full Text] [Related]
11. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
[TBL] [Abstract][Full Text] [Related]
13. Selection of HLA-A2 restricted CML28 peptide by artificial antigen-presenting cells.
Mao H; Geng Z; Liu W; Sun H; Huang W
J Immunother; 2008 Jun; 31(5):487-90. PubMed ID: 18463536
[TBL] [Abstract][Full Text] [Related]
14. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
15. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
18. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
[TBL] [Abstract][Full Text] [Related]
19. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
[TBL] [Abstract][Full Text] [Related]
20. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]